Association of decreased serum vasostatin-2 level with ischemic chronic heart failure and with MACE in 3-year follow-up: Vasostatin-2 prevents heart failure in myocardial infarction rats
Association of decreased serum vasostatin-2 level with ischemic chronic heart failure and with MACE in 3-year follow-up: Vasostatin-2 prevents heart failure in myocardial infarction rats
复制标题
3 年随访中血清 Vasostatin-2 水平降低与缺血性慢性心力衰竭和 MACE 的关联：Vasostatin-2 可预防心肌梗死大鼠的心力衰竭
DOI：
10.1016/j.ijcard.2016.06.065
复制
发表时间：
2016-10-15
影响因子：
3.5
通讯作者：
Lu, Lin
中科院分区：
文献类型：
--
作者：
Pan, Wen Qi;He, Yu Hu;Lu, Lin
背景：我们研究了先前心肌梗死（MI）和3年随访的MACE患者的血清血管毒素-2水平是否与慢性心力衰竭（CHF）有关。在动物实验中评估了血管固醇-2对缺血性HF的生物学作用。方法：排除受试者不合格后，该研究包括450例CHF和先前MI的患者，以及149个健康对照。分析了血清血管毒素-2水平。 CHF患者进行了三年的跟踪，并记录了重大不良心脏事件（MACE），定义为重新施加，目标血管血运重建，心血管死亡和需要住院的难治性HF。重新检查：尤其，血清Vasostatin-2水平降低了CHF CHF患者。比对照组中的CHF患者和没有对照的患者观察到了显着差异（均为p <0.05）。 vasostatin-2水平与HF阶段（Spearman的r = -0.288，p <0.05），LVEF（r = 0.377，p <0.05）和ProbNP水平（r = -0.294，p <0.05）相关。多变量逻辑回归分析表明，血管固醇-2，常规危险因素，HF阶段的严重程度和LVEF与CHF患者的MACE独立相关。在MI大鼠中，每隔一天对腹膜内注射vasostatin-2（100 mu G）或PBS，按超声心动图，2个月后进行血液动力学分析。与PBS相比，血管固醇-2治疗可阻止MI大鼠缺血性HF，并伴随着梗塞大小，重塑，纤维化和炎症的降低，主要是通过抑制RHO，WNT和TLR-4途径以及肾素 - 血管素系统的调节。血清血管固醇-2水平降低与缺血性CHF有关，并且在三年的随访中与MACE有关。腹膜内注射血管固醇-2可预防MI大鼠缺血性HF。 （c）2016年Elsevier Ireland Ltd.保留所有权利。
Background: We investigated whether serum vasostatin-2 level is related to chronic heart failure (CHF) in patients with previous myocardial infarction (MI) and MACE in 3-year follow-up. The biological effect of vasostatin-2 on ischemic HF was evaluated in animal experiments.Methods: After exclusion of the subjects not eligible, this study included 450 patients with CHF and previous MI, and 149 healthy controls. Serum vasostatin-2 level was analyzed. CHF patients were followed up for three years and major adverse cardiac events (MACE) were recorded, defined as reinfarction, target-vessel revascularization, cardiovascular death and refractory HF requiring hospitalizations.Results: Notably, serum vasostatin-2 level was decreased in CHF patients than in controls, and significant difference was observed between CHF patients with MACE and those without (both P < 0.05). Vasostatin-2 level was correlated with HF stages (Spearman's r = -0.288, P < 0.05), LVEF (r = 0.377, P < 0.05) and proBNP level (r=-0.294, P < 0.05). Multivariable logistic regression analysis suggested that vasostatin-2, conventional risk factors, severity of HF stages and LVEF were independently associated with MACE in CHF patients. Vasostatin-2 (100 mu g) or PBS was injected intraperitoneally every other day in MI rats, follow by echocardiography, hemodynamic analysis after 2 months. Compared with PBS, vasostatin-2 treatment prevented ischemic HF in MI rats, accompanied with reduction of infarct size, remodeling, fibrosis and inflammation, mainly through inhibition of Rho, Wnt and TLR-4 pathways and modulation of renin-angiotensin system.Conclusion: Decreased serum vasostatin-2 level is associated with ischemic CHF and with MACE in three-year follow-up. Intraperitoneal injection of vasostatin-2 protects against ischemic HF in MI rats. (C) 2016 Elsevier Ireland Ltd. All rights reserved.